Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 30, 2022
Daily News
November 30, 2022
- Aricept Label Now Modified for Lewy Body Dementia Indication: Eisai
November 30, 2022
- MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
- Shionogi Curbs Shipments of Xofluza 10 mg on Big Demand
November 30, 2022
- Parexel Poised to Upsize Japan Workforce by 10%-Plus as Opportunities Expand
November 30, 2022
- SanBio Links Arms with Keio University on Alzheimer’s Drug Research
November 30, 2022
- No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
- Building Delivery Scheme for Disease-Modifying Drugs for Alzheimer’s Is Critical: Academic Societies
November 30, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…